- Home
- AMRN vs ABEO Comparison
AMRN vs ABEO Comparison
Compare AMRN & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | ABEO |
|---|---|---|
| Founded | 1989 | 1974 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.3M | 312.6M |
| IPO Year | 1998 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AMRN | ABEO |
|---|---|---|
| Price | $14.40 | $5.40 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $20.00 |
| AVG Volume (30 Days) | 41.8K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.00 | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | ★ $181,104,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | $1.26 | $145.42 |
| P/E Ratio | ★ N/A | $5.45 |
| Revenue Growth | 39.22 | ★ 258.18 |
| 52 Week Low | $9.44 | $4.00 |
| 52 Week High | $20.90 | $7.54 |
Technical Indicators
Market Signals| Indicator | AMRN | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 58.61 |
| Support Level | $13.69 | $5.24 |
| Resistance Level | $14.49 | $5.62 |
| Average True Range (ATR) | 0.60 | 0.24 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 25.62 | 68.15 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.